Skip to main content

Table 3 Studies describing in-hospital mortality in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Setting Author Study groups (n) In-Hospital Mortality Reported P-value Ref
Tertiary care center Akhabue et al. (2011) Cefepime resistant P. aeruginosa (213) 20% 0.007 [61]
Susceptible P. aeruginosa (2316) 13%
Brooklyn Antibiotic Resistance Task Force (2002) Carbapenem resistant P. aeruginosa (10) 20% > 0.05 (NS) [60]
Susceptible P. aeruginosa (10) 10%
Cao et al. (2004) MDR P. aeruginosad (44) 55% 0.05 [57]
Susceptible P. aeruginosa (68) 16%
Eagye et al. (2009) Meropenem resistant P. aeruginosa (58) 31% 0.152a [53]
Meropenem susceptible P. aeruginosa (125) 15%
Meropenem resistant P. aeruginosa (58) 31% 0.01a
Control (57) 9%
Evans et al. (2007) Resistant P. aeruginosae (47) 15% 0.43 [71]
Susceptible P. aeruginosa (73) 21%
Furtado et al. (2011) SPM-1-producing imipenem resistant P. aeruginosa (5) 60% 0.59 [68]
Non-SPM-1-producing susceptible P. aeruginosa (24) 75%
Gasink et al. (2006) Fluoroquinolone resistant P. aeruginosa (320) 24% 0.004 [64]
Fluoroquinolone susceptible P. aeruginosa (527) 16%
Hirakata et al. (2003) blaIMP-positive P. aeruginosa (69) 30.4% 0.41 [69]
blaIMP-negative P. aeruginosa (247) 25.5%
Lautenbach et al. (2010) Imipenem resistant P. aeruginosa (253) 17% 0.01 [63]
Imipenem susceptible P. aeruginosa (2289) 13%
Morales et al. (2012) MDR P. aeruginosaf (134) 25% < 0.05 [49]
Susceptible P. aeruginosa (149) 13%
Resistant P. aeruginosa (119) 22% <0.05
Susceptible P. aeruginosa (149) 13%
Peña et al. (2013) Non-MDR P. aeruginosa (27) 55% 0.33 [56]
MDR P. aeruginosag (56) 50%
Scheetz et al. (2006) Fluoroquinolone resistant P. aeruginosa (79) 32% 0.731 [65]
Fluoroquinolone susceptible P. aeruginosa (136) 29%
Tam et al. (2010) MDR P. aeruginosah (25) 56% 0.001 [13]
Susceptible P. aeruginosa (84) 17%
Zavascki et al. (2006) MBL-carrying P. aeruginosa (86) 51.2% 0.003 [70]
Non-MBL-carrying P. aeruginosa (212) 32.1%
ICU Lambert et al. (2011) Ceftazidime resistant P. aeruginosa (362)b 43% NR [31]
Susceptible P. aeruginosa (1251)b 37%
Ceftazidime resistant P. aeruginosa (82)c 41%
Susceptible P. aeruginosa (280)c 39%
Furtado et al. (2009) Imipenem resistant P. aeruginosa (63) 49% 0.02 [62]
Control (182) 34%
Kaminski et al. (2011) Ureido/carboxypenicillin resistant P. aeruginosa (70) 43% 0.56 [66]
Ureido/carboxypenicillin susceptible P. aeruginosa (153) 44%
Paramythiotou et al. (2004) MDR P. aeruginosai (34) 47% 0.8 [54]
Control (34) 50%
Trouillet et al. (2002) Piperacillin resistant P. aeruginosa (34) 59% > 0.05 (NS) [67]
Piperacillin susceptible P. aeruginosa (101) 50%
Tumbarello et al. 2013 MDR P. aeruginosaj (42) 60% 0.01 [55]
Susceptible P. aeruginosa (68) 35%
  1. aAdjusted for time at risk; bPatients with pneumonia; cPatients with bloodstream infections; dAbsence of susceptibility to three or more antibiotics: ceftazidime, cefepime, piperacillin, ciprofloxacin, gentamicin, and imipenem or meropenem; eAbsence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to carbapenems, β-lactams, quinolones, tobramycin, and gentamicin; gAbsence of susceptibility to one or more agent in three or more anti-pseudomonal antimicrobial categories (carbapenems, β-lactams, quinolones, tobramycin, and gentamicin); hAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones; iAbsence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin; jAbsence of susceptibility to one or more antipseudomonal agent in 3 or more of the following categories: β-lactam/β-lactamase inhibitors, cephalosporins, carbapenems, quinolones and aminoglycosides.